3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
CNS
1
Breast
1
Conditions
Breast Neoplasms
58
Neoplasm Metastasis
21
Carcinoma, Non-Small-Cell Lung
9
Stomach Neoplasms
8
Brain Neoplasms
8
Colorectal Neoplasms
7
Triple Negative Breast Neoplasms
4
Pancreatic Neoplasms
4
Ovarian Neoplasms
4
Endometrial Neoplasms
4
Salivary Gland Neoplasms
3
Recurrence
3
Neoplasms
3
Esophageal Neoplasms
3
Advanced Breast Cancer
3
Adenocarcinoma
3
Prostatic Neoplasms
2
Meningeal Carcinomatosis
2
HER2-positive Gastric Cancer
2
Colonic Neoplasms
2
Breast Cancer With Brain Metastasis
2
Advanced Solid Tumor
2
Adenocarcinoma Of Esophagus
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Unresectable Locally Recurrent Breast Cancer
1
Interventions
Temozolomide
19
Magnetic Resonance Spectroscopy
15
Radiotherapy
14
Specimen Handling
13
Radiation
9
Biopsy
5
pembrolizumab
4
Radiotherapy, Intensity-Modulated
4
Nivolumab
4
Bevacizumab
4
vorasidenib
3
trametinib
3
Surgical Procedures, Operative
3
Spinal Puncture
3
tovorafenib
2
dabrafenib
2
Restraint, Physical
2
Leukapheresis
2
Ipilimumab
2
Genetic Therapy
2
Fluorodeoxyglucose F18
2
Eflornithine
2
Craniotomy
2
Carboplatin
2
14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene
2
vocimagene amiretrorepvec
1
veliparib
1
trastuzumab deruxtecan
1
tozuleristide
1
tocilizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Astrocytoma
×
trastuzumab deruxtecan
×
1 year
×
Clear all
NCT05417594
2026-06-02
CERTIS1
AstraZeneca
Phase 1/2
Recruiting
695 enrolled